Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07134101

PHASE2

Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)

Sponsor: The First Affiliated Hospital with Nanjing Medical University

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if combining serplulimab (PD-1 inhibitor) with bevacizumab and short-course total neoadjuvant therapy (TNT) works to treat locally advanced mid-to-low rectal cancer in adults. It will also learn about the safety of this combination. The main questions it aims to answer are: Does adding bevacizumab to serplulimab and TNT increase the complete remission rate (cCR + pCR) compared with serplulimab and TNT alone? What medical problems do participants have when receiving these treatments? Researchers will compare: Experimental group: serplulimab + bevacizumab + chemotherapy + short-course radiotherapy Control group: serplulimab + chemotherapy + short-course radiotherapy Participants will: Receive either the experimental or control regimen for about 4-5 months before surgery or a watch-and-wait approach if complete response is achieved Undergo treatment in cycles that include chemotherapy, immunotherapy (and bevacizumab if in the experimental group), and short-course radiotherapy Visit the clinic regularly for check-ups, blood tests, imaging, endoscopy, and to monitor side effects Be followed for up to 5 years after treatment to assess cancer control, organ preservation, and survival outcomes

Official title: Neoadjuvant Chemoradiotherapy Combined With Serplulimab With or Without Bevacizumab for Locally Advanced Rectal Cancer: A Single-Center, Open-Label, Phase II Randomized Trial

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

138

Start Date

2025-09-01

Completion Date

2030-08-31

Last Updated

2025-08-29

Healthy Volunteers

Conditions

Colorectal Cancer (Diagnosis)

Interventions

DRUG

Serplulimab

Serplulimab 300 mg IV on Day 1

DRUG

Bevacizumab

Bevacizumab 5 mg/kg IV on Day 1

RADIATION

Short-Course Radioterapy

25 Gy in 5 fractions over 1 week

DRUG

Chemotherapy (CAPOX or capecitabine)

Capecitabine: 800 mg/m² orally, twice daily (BID), on Days 1-14 of each cycle Oxaliplatin: 130 mg/m² intravenous infusion, on Day 1 of each cycle

Inclusion Criteria: Participants must meet all of the following criteria to be eligible for the study: 1. Age: 18 to 75 years old. 2. Diagnosis: Pathologically confirmed rectal adenocarcinoma with proficient mismatch repair (pMMR) / microsatellite stable (MSS) status, based on biopsy of the primary tumor. 3. Disease Stage: Untreated, preoperative clinical stage cT2-T4 and/or N+, M0 (AJCC 8th edition), unsuitable for initial local excision to achieve radical cure. 4. Tumor Location: Tumor within 8 cm from the anal verge, or assessed by surgeons as not suitable for immediate sphincter-preserving surgery. 5. Organ Preservation Intent: Strong desire for sphincter preservation and willingness to accept close surveillance for at least 2 years after chemoradiotherapy. 6. Surgical Candidacy: Agrees to undergo radical surgery and judged by surgeon to have no contraindication to surgery. 7. Cancer History: No concurrent multiple primary malignancies. 8. Measurable Lesions: At least one measurable or evaluable lesion according to RECIST v1.1 criteria. 9. Life Expectancy: ≥ 3 months. 10. Performance Status: ECOG performance status score of 0-1. 11. Compliance: Good compliance and willingness to sign written informed consent. Exclusion Criteria: Participants will be excluded if any of the following conditions apply: 1. Molecular Subtype: Rectal cancer with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) status. 2. Autoimmune Disease: Active, known, or suspected autoimmune disease. 3. Immunodeficiency: Known history of primary immunodeficiency. 4. Transplant History: History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. 5. Pregnancy or Lactation: Pregnant or breastfeeding women. 6. Urgent Surgical Indications: Intestinal perforation, gastrointestinal bleeding, or other conditions requiring emergency surgery. 7. Uncontrolled Comorbidities, including but not limited to: HIV infection (HIV antibody positive) Active or poorly controlled severe infection Active hepatitis Severe or uncontrolled systemic diseases (e.g., severe psychiatric or neurological disorders, epilepsy, dementia, unstable or decompensated respiratory, cardiovascular, hepatic, or renal disease, uncontrolled hypertension ≥ CTCAE Grade 2 despite medication) Active bleeding or recent thrombotic disease requiring therapeutic anticoagulation, or bleeding tendency, or coagulation abnormalities (INR \> 1.5 × ULN, APTT \> 1.5 × ULN) 8. Laboratory Abnormalities at Baseline: Hemoglobin \< 80 g/L Absolute neutrophil count (ANC) \< 1.5 × 10⁹/L Platelets \< 80 × 10⁹/L ALT or AST \> 2.5 × ULN ALP \> 2.5 × ULN Total bilirubin ≥ 1.5 × ULN Serum creatinine ≥ 1 × ULN 9. Allergy: Known hypersensitivity to any component of the investigational drugs. 10. Other Clinical Trial Participation: Currently enrolled in another interventional drug clinical trial. 11. Other Conditions: Any other condition judged by the investigator to make the patient unsuitable for the study.

Clinical Research Directory

Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)

Summary

Key Details

Conditions

Interventions

Eligibility Criteria